全文获取类型
收费全文 | 519篇 |
免费 | 47篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 3篇 |
妇产科学 | 1篇 |
基础医学 | 57篇 |
口腔科学 | 7篇 |
临床医学 | 47篇 |
内科学 | 184篇 |
皮肤病学 | 4篇 |
神经病学 | 79篇 |
特种医学 | 2篇 |
外科学 | 48篇 |
综合类 | 9篇 |
预防医学 | 32篇 |
眼科学 | 6篇 |
药学 | 41篇 |
肿瘤学 | 46篇 |
出版年
2022年 | 3篇 |
2021年 | 13篇 |
2020年 | 6篇 |
2019年 | 10篇 |
2018年 | 19篇 |
2017年 | 11篇 |
2016年 | 19篇 |
2015年 | 11篇 |
2014年 | 19篇 |
2013年 | 21篇 |
2012年 | 31篇 |
2011年 | 32篇 |
2010年 | 8篇 |
2009年 | 5篇 |
2008年 | 29篇 |
2007年 | 23篇 |
2006年 | 16篇 |
2005年 | 20篇 |
2004年 | 25篇 |
2003年 | 21篇 |
2002年 | 25篇 |
2001年 | 13篇 |
2000年 | 26篇 |
1999年 | 17篇 |
1998年 | 5篇 |
1997年 | 11篇 |
1996年 | 7篇 |
1995年 | 4篇 |
1993年 | 3篇 |
1992年 | 6篇 |
1991年 | 9篇 |
1990年 | 7篇 |
1989年 | 4篇 |
1988年 | 7篇 |
1987年 | 5篇 |
1985年 | 3篇 |
1984年 | 4篇 |
1979年 | 2篇 |
1974年 | 5篇 |
1973年 | 2篇 |
1972年 | 6篇 |
1971年 | 3篇 |
1970年 | 4篇 |
1969年 | 4篇 |
1968年 | 4篇 |
1967年 | 4篇 |
1966年 | 5篇 |
1964年 | 2篇 |
1963年 | 2篇 |
1962年 | 5篇 |
排序方式: 共有567条查询结果,搜索用时 7 毫秒
11.
Establishing a multidisciplinary diabetic foot team in a large tertiary hospital: a workshop 下载免费PDF全文
Avivit Cahn Ofer Elishuv Keren Olshtain‐Pops 《Diabetes/metabolism research and reviews》2014,30(5):350-353
Every year, over 1 million people with diabetes lose a leg due to diabetic foot disease. Most amputations are preceded by a foot ulcer. Causes for the development of foot ulcers are generally multifactorial and may include neuropathy, peripheral vasculopathy, abnormal foot mechanics and infection. Multidisciplinary approach to the patient with acute diabetic foot is mandatory and has been shown to reduce amputation rate. In our article we describe the establishment of a multidisciplinary diabetic foot team in a large tertiary hospital and its outcomes. Copyright © 2014 John Wiley & Sons, Ltd. 相似文献
12.
Avivit Cahn MD Itamar Raz MD Marc Bonaca MD Ofri Mosenzon MD Sabina A. Murphy MPH Ilan Yanuv MSc Aliza Rozenberg MA John P. H. Wilding MD Deepak L. Bhatt MD Darren K. McGuire MD Ingrid A. M. Gause-Nilsson MD Martin Fredriksson MD Peter A. Johansson MSc Gyorgy Jermendy MD Samy Hadjadj MD Anna Maria Langkilde MD Marc S. Sabatine MD Stephen D. Wiviott MD Lawrence A. Leiter MD 《Diabetes, obesity & metabolism》2020,22(8):1357-1368
13.
Lioure B Béné MC Pigneux A Huynh A Chevallier P Fegueux N Blaise D Witz B Delain M Cornillon J Luquet I Blanchet O Cornillet-Lefebvre P Carré M Hunault M Larosa F Lamy T Randriamalala E Ojeda-Uribe M Berthou C Fornecker L Harousseau JL Bouscary D Ifrah N Cahn JY;GOELAMS 《Blood》2012,119(12):2943-2948
The LAM2001 phase 3 trial, involving 832 patients with acute myeloid leukemia (AML; median: 46 years) proposed HLA-identical sibling allograft HSCT for all patients with an identified donor. The trial compared reduced-intensity conditioning (RIC) for patients older than 50 years of age (N = 47) and myeloablative conditioning for younger patients (N = 117). BM HSCT was performed in the younger patients, while the older ones received a consolidation course, followed by peripheral blood allo-HSCT using RIC. The incidence of grade II-IV acute GVHD, was 51.9% (95% confidence interval [CI]: 42.1-61.8) and 11.3% (1.6-21.2) after myeloablative or RIC, respectively (P < .0001) and that of chronic GVHD 45.8% (95% CI: 34.8-56.7) and 41.7% (24.7-58.6; NS). Cumulative incidence of nonrelapse mortality at 108 months was 15.8% (95% CI: 9.8-23.2) for myeloablative, and 6.5% (0.2-16.2) for RIC (NS). CI of relapse at 108 months was 21.7% (95% CI: 13.9-28.6) and 28.6% (16.5-43.4; NS). Overall survival at 108 months was 63.4% (95% CI: 54.6-72.2) and 65.8% (52.2-72.2), respectively, after myeloablative or RIC (NS). RIC peripheral blood stem cell allo-HSCT is prospectively feasible for patients between the ages of 51 and 60 years without excess of relapse or nonrelapse mortality, and compares favorably with myeloablative marrow allo-HSCT proposed to younger patients. 相似文献
14.
Natarajan-Amé S Park S Ades L Vey N Guerci-Bresler A Cahn JY Etienne G Bordessoule D Ravoet C Legros L Cheze S Stamatoullas A Berger E Schmidt A Charbonnier A Chaury MP Braun T Fenaux P Dreyfus F;Groupe Francophone des Myélodysplasies 《British journal of haematology》2012,158(2):232-237
Marrow cells from patients with higher-risk myelodysplastic syndrome (MDS) exhibit constitutive nuclear factor (NF)-κB activation. The proteasome inhibitor, bortezomib, has limited efficacy as a single agent in acute myeloid leukaemia. Its activity on leukaemic cell lines is potentiated by chemotherapy. We treated 43 higher-risk MDS patients with bortezomib (1·5 mg/m(2) , days 1, 4, 8 and 11) and low dose cytarabine arabinoside (LDAC; 10 mg/m(2) , then 20 mg/m(2) from days 1-14), every 28 d for four cycles. Median follow-up was 29·7 months. Responses were seen in 12 of the 43 patients (28%), including complete response (CR, n = 1), marrow-CR (n = 3), partial response (PR, n = 5) and haematological improvement (HI, n = 3). Responses were seen in 12 (36%) of the 33 previously untreated patients (11% CR, 13% PR, 2·5% HI), compared to none in the 12 previously treated patients (P < 0·01). Responders had better overall survival (median 18·2 vs. 10 months). One CR and 3 marrow-CRs were seen in patients with complex karyotypes. Main toxicity was haematological, responsible for infection in six patients and bleeding in 3. Three patients with Grade 1-2 pre-treatment haematotoxicity developed Grade 3-4 toxicity. Neuropathy was seen in 12% of patients. The addition of bortezomib to LDAC in higher-risk MDS may improve results obtained with LDAC alone, especially in patients with unfavourable karyotypes. 相似文献
15.
16.
Avivit Cahn MD Stephen D. Wiviott MD Ofri Mosenzon MD Sabina A. Murphy MPH Erica L. Goodrich MS Ilan Yanuv MSc Aliza Rozenberg MA John P. H. Wilding MD Lawrence A. Leiter MD Deepak L. Bhatt MD Darren K. McGuire MD Leon Litwak MD Adriaan Kooy MD Ingrid A. M. Gause-Nilsson MD Martin Fredriksson MD Anna Maria Langkilde MD Marc S. Sabatine MD Itamar Raz MD 《Diabetes, obesity & metabolism》2021,23(1):29-38
17.
Oliver Sartor MD Daniel Heinrich MD Neil Mariados MD Maria José Méndez Vidal MD Daniel Keizman MD Camilla Thellenberg Karlsson MD Avivit Peer MD Giuseppe Procopio MD Stephen J. Frank MD Kalevi Pulkkanen MD Eli Rosenbaum MD Stefano Severi MD José Trigo MD Lucia Trandafir MD Volker Wagner MD Rui Li MS Luke T. Nordquist MD 《The Prostate》2019,79(14):1683-1691
18.
A patient with well-defined acute HIV infection who developed concomitant pulmonary tuberculosis during the retroviral acute syndrome is reported here. In this patient high levels of T-regulatory cells (Tregs) and a low proliferation response to M. tuberculosis were initially detected, which normalized throughout follow-up. This case calls for the consideration of tuberculosis in patients in the early stages of HIV, and emphasizes the need for further study of the potential causal relationship between Treg cells and the risk of TB reactivation in HIV patients. 相似文献
19.
20.
Moyle GJ DeJesus E Cahn P Castillo SA Zhao H Gordon DN Craig C Scott TR;Ziagen Once-Daily in Antiretroviral Combination Therapy 《Journal of acquired immune deficiency syndromes (1999)》2005,38(4):417-425
The long intracellular half-life of abacavir (ABC) supports its once-daily use, and this would be expected to simplify treatment if ABC could be given as part of a complete once-daily regimen. A randomized double-blind clinical trial compared the efficacy and safety of 600 mg of ABC administered once daily (n = 384) versus 300 mg of ABC administered twice daily (n = 386) in combination with 300 mg of lamivudine (3TC) and 600 mg of efavirenz (EFV) administered once daily in antiretroviral-naive patients over 48 weeks. The baseline median plasma HIV-1 RNA level was 4.89 log10 copies/mL (44% with viral load >100,000 copies/mL), and the median CD4 cell count was 262 cells/mm. ABC administered once daily was non-inferior to the twice-daily regimen, with 66% and 68% of patients in these respective treatment arms achieving a confirmed plasma HIV-1 RNA level <50 copies/mL (95% confidence interval: -8.4%, 4.9%). The ABC once-daily and twice-daily regimens were similar with respect to infrequency of virologic failure (10% vs. 8%), emergence of resistance mutations, CD4 cell increases from baseline (median, 188 vs. 200 cells/mm), safety profile, and incidence of ABC-related hypersensitivity reactions (9% vs. 7%). ABC administered once daily in combination with 3TC and EFV administered once daily was non-inferior to the ABC twice-daily dosing schedule when combined with 3TC and EFV over 48 weeks. 相似文献